



*Central Zone*

## *Pathology and Laboratory Medicine Memorandum*

---

To: Nova Scotia Healthcare Providers and Health Service Directors  
From: Dr. Mike Carter, Medical Director of Molecular Diagnostics  
Dr. Tanya Gillan, Clinical Director of Molecular Diagnostics  
Randy Veinotte, Esoteric Laboratory Manager  
Date: December 12, 2022  
Subject: New Expanded Solid Tumor Panel

The Molecular Diagnostics laboratory (MDL) is now offering an expanded solid tumor next-generation sequencing panel (AmpliSeq for Illumina Focus panel). This new assay will offer targeted sequencing of 52 genes to help identify mutations that predict response to different conventional and targeted cancer therapies. In some cases, it will also provide diagnostic and prognostic information which will be of additional help in choosing optimal / personalized therapy for patients with solid tumors.

The new panel can detect:

- Small mutations, such as BRAF V600E, KRAS G12C, and EGFR exon 19 deletions
- Gene fusions, e.g. in ALK, ROS1, RET, NTRK1-3, and METex14 skipping
- Copy number gains/amplifications, e.g., in HER2 (ERBB2) and EGFR

Below are the new test costs for NGS related testing, including a new fee for reanalysis and/or addition of other genes/panels not included in the original analysis.

NGS Solid Tumor Panel 52 genes – \$1056.18  
NGS Solid Tumor Panel 15 genes – \$842.37  
NGS Myeloid Panel – \$906.39  
NGS IGHV – \$793.61  
NGS BRCA – \$777.31  
NGS Myeloid Reanalysis – \$489.56  
NGS Solid Tumor Reanalysis – \$329.89

No changes are required from the Healthcare Provider when filling out the molecular requisition as the appropriate panel will be ordered by MDL staff for the test being requested.

If you have any questions, please contact Dr. Carter at 902-473-4641 or [michaeld.carter@nshealth.ca](mailto:michaeld.carter@nshealth.ca)